IDH2 and glioblastoma: A post-hoc analysis from the CATNON study population, identifying 159 IDH-wt tumors with molecular features of a IDH-wt glioblastoma, similarly revealed no additional benefit of temozolomide in regard to PFS and OS compared to radiotherapy alone [32].